{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-023741","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.687905+00:00","generated_at":"2026-05-26T09:11:05.905347+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio reports Q4 net loss of $1.40/share; Attruby launch with 1,028 scripts, EU approval triggers $75M milestone","bullets":["Attruby (acoramidis) prescriptions reached 1,028 from 516 prescribers as of Feb 17; EU approval on Feb 10 triggered $75M milestone.","Q4 2024 net loss $265.1M ($1.40 EPS); full-year net loss $535.8M ($2.88 EPS).","Q4 revenue $5.9M including $2.9M Attruby sales; full-year revenue $221.9M driven by $207.7M from Bayer/Kyowa Kirin deals.","Cash, cash equivalents and short-term restricted cash $681.2M at Dec 31, 2024, up from $392.6M at Dec 31, 2023.","Three Phase 3 trials (LGMD2I, ADH1, achondroplasia) fully enrolled; last participant last visit expected 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-023741","json":"https://secwatch.observer/filing/0000950170-25-023741.json","markdown":"https://secwatch.observer/filing/0000950170-25-023741.md","text":"https://secwatch.observer/filing/0000950170-25-023741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025023741/0000950170-25-023741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025023741/bbio-20250220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T09:11:05.905347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}